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Abstract: Colorectal cancer (CRC) shows aggregation in some families but no alterations in the
known hereditary CRC genes. We aimed to identify new candidate genes which are potentially
involved in germline predisposition to familial CRC. An integrated analysis of germline and tumor
whole-exome sequencing data was performed in 18 unrelated CRC families. Deleterious single
nucleotide variants (SNV), short insertions and deletions (indels), copy number variants (CNVs)
and loss of heterozygosity (LOH) were assessed as candidates for first germline or second somatic
hits. Candidate tumor suppressor genes were selected when alterations were detected in both
germline and somatic DNA, fulfilling Knudson’s two-hit hypothesis. Somatic mutational profiling
and signature analysis were also performed. A series of germline-somatic variant pairs were detected.
In all cases, the first hit was presented as a rare SNV/indel, whereas the second hit was either a
different SNV (3 genes) or LOH affecting the same gene (141 genes). BRCA2, BLM, ERCC2, RECQL,
REV3L and RIF1 were among the most promising candidate genes for germline CRC predisposition.
The identification of new candidate genes involved in familial CRC could be achieved by our
integrated analysis. Further functional studies and replication in additional cohorts are required to
confirm the selected candidates.
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1. Introduction
Colorectal cancer (CRC) is one of the most common and lethal malignant neoplasms worldwide,
accounting for 8% of all cancer-related deaths [1]. Developed countries are the most affected, with almost
55% of diagnosed cases, although with better survival rates, since 52% of deaths occur in less-developed
regions [2]. The lifetime risk of developing CRC is between 5–6%, but an incidence rise is expected in the
coming years, due to higher life expectancy.
Genetic and environmental factors are involved in CRC predisposition. Environmental contributors
include alcohol, tobacco and fat intake, among others [3]. Inherited genetic variation reaches 35% of
susceptibility according to twin studies [4]. Predisposition can be classified according to population
frequency and associated disease risk into high- and low-penetrant variants. High-penetrant variants
are rare and have a large effect on the predisposition to the disease. Regarding CRC, well-defined
genes such as APC, MUTYH, the DNA polymerases POLE and POLD1 and the DNA mismatch repair
(MMR) family (MSH2, MLH1, MSH6 and PMS2) are affected by these mutations, causing well-known
hereditary syndromes (familial adenomatous polyposis, MUTYH-associated polyposis, polymerase
proofreading-associated polyposis and Lynch syndrome, respectively) [5]. However, only 5% of CRC cases
are explained by this kind of variation due to its low frequency in the population. Low-penetrance genetic
variation, mainly identified in genome-wide association studies, is characterized by a high prevalence in
the population and a weak deleterious effect. However, collectively, all identified low-penetrance variants
contribute significantly to CRC susceptibility, accounting for 5–10% of the heritability to this disease [6].
Familial CRC can be defined as a heterogeneous condition defined by patients with a family history
for this neoplasia without alterations in the known hereditary CRC genes. Its etiology is not completely
understood yet. The genes responsible are likely to be fairly uncommon but penetrant enough
to explain the autosomal dominant patterns of inheritance reported [6]. Recent studies identified
potentially implicated genes, including NTHL1, GREM1 and RNF43, as the most remarkable [7].
The two-hit hypothesis for cancer development was formulated by Alfred G. Knudson in 1971 [8].
Genes with a loss of function followed by a rapid acceleration of the oncogenic phenotype were named
tumor suppressor genes (TSGs). Allelic inactivation can take place as a single nucleotide variant
(SNV), a short insertion or deletion (indel), an anomalous methylation or a copy number variant
(CNV) [9]. Regarding their distribution, duplications are usually more abundant in healthy individuals
than deletions because of their commonly milder phenotypic effect [10]. However, considering
Knudson’s hypothesis, a putative second hit would involve a deletion, thus leading to the somatic loss
of heterozygosity (LOH).
Commonly used in recent years for the cost-effective discovery of pathogenic SNVs and indels,
whole-exome sequencing (WES) has also marked a turning point for CNV and LOH detection.
Despite the challenge of the uneven coverage distribution along the genome, WES approaches have
emerged as a solid option for germline CNV calling [11], recently obtaining significant results in CRC
predisposition [12]. Regarding tumor LOH detection, classic approaches were based on microsatellite
markers around the gene of interest. However, ALFRED (allelic loss featuring rare damaging), a novel
approach using WES data, has been recently developed to predict putative genes affected by LOH.
It is a statistical method capable of inferring LOH status by testing for the allelic imbalance between
germline and tumor sequencing data [13].
By means of the development of a combined germline–tumor WES analysis, the purpose of
this study was the identification of novel candidate genes involved in germline predisposition to
familial CRC. The potential TSG role of the selected candidates was assessed according to Knudson’s
two-hit hypothesis.
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2. Results
2.1. Two-Hit Prioritization Strategy Identified New Candidate Genes for CRC Germline Predisposition
WES was performed in 18 unrelated familial CRC patients both in germline and tumor DNA.
Prior to data analysis, quality control verifications were carried out. All germline samples yielded
good results, with a mean coverage higher than 95× in all cases, resulting in approximately 4 gigabases
sequenced per sample. However, two of the tumor samples (FAM22 and H461) showed a significant
low value of shared exome regions sequenced (Figure S1) and were finally discarded.
An in-house pipeline was used to identify and filter genetic variants, including SNVs, indels,
CNVs and LOHs, in germline and tumor WES data. Those rarest and potentially harmful variants with
a function compatible with CRC susceptibility were highlighted. The prioritization strategy selected
as candidates those genes affected by two hits according to Knudson’s hypothesis and, therefore,
those which are susceptible to have a TSG role.
Regarding germline CNVs, after their integrated calling using two different algorithms and
frequency filtering, seven different rare variants were selected (five duplications and two deletions)
(Table S1). However, functions and previously linked phenotypes of the affected genes were not
sufficiently relevant to CRC, resulting in their not being further considered as putative germline
mutational events. On the other hand, SNVs and indels recorded a total of 494 and 42 germline
variants, respectively, after filtering. Thus, only the first hits in the form of SNVs and indels were
finally taken under consideration, whereas second hits were selected from the whole spectrum of
genetic alterations analyzed (SNV, indels and LOHs).
A total of 143 genes carried a germline–tumor pair of potentially disruptive variants in our
samples. Among them, a germline SNV followed by a different somatic SNV was identified in ADCY8,
HSPG2 and TTN. No indel was found as a tumor second hit. The TTN gene encodes for a giant protein
of more than 30,000 amino acids, thus having a higher probability of accumulating genetic alterations
simply by chance. Considering also its function as a muscular protein, it was discarded as a potential
cause for CRC predisposition. Therefore, ADCY8 and HSPG2 were selected as the most promising
candidates from this double germline–tumor disrupting SNV approach (Table 1).
On the other hand, 141 genes were predicted to be affected by LOH as somatic mutational
events with an SNV/indel as a germline first hit (133 SNVs and 8 indels) (Table S2). Interestingly,
LOH was also predicted for HSPG2 gene, thus presenting both kinds of second hits. Among the
141 germline–tumor pairs of potentially disruptive variants, we pursued an additional prioritization
process to better select candidate genes with a plausible implication in CRC predisposition. In this
regard, manual curation taking into account protein function compatible with CRC or cancer, as well as
previously reported links with susceptibility to CRC or other neoplasms, was considered. A summary
of the final 16 functionally prioritized candidates for germline SNV and tumor LOH prediction is
shown in Table 2. Interestingly, DNA repair was one of most enriched functions among candidates,
with 7 out of 16 genes (43.8%) linked to this cellular mechanism (BRCA2, BLM, ERCC2, PARP2, RECQL,
REV3L and RIF1). It is also interesting to highlight candidate genes involved in hereditary cancer
(BRCA2, BLM, ERCC2, SMARCA4) or connected to inherited CRC, such as Cowden syndrome (SEC23B)
and Peutz–Jeghers syndrome (STK11IP). Taking this into account, 10 genes were selected as the best
candidates for CRC germline predisposition from the approach of germline SNV/indel and somatic
LOH including BRCA2, BLM, ERCC2, PARP2, RECQL, REV3L, RIF1, SEC23B, SMARCA4 and STK11IP.
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Table 1. Description of the genes carrying a potentially disruptive germline SNV (single nucleotide variant) and a different SNV in the matched-tumor sample.
Gene Family RefSeq Transcript Hit Genetic Variant Path. Tools DAMpred ExAC Freq. Protein Domain Protein Function
ADCY8 FAMN4 NM_001115.2
1st c.1747G>Ap.(Glu583Lys) 5/6 − 21/60,697
Adenylyl cyclase
class-3/4/guanylyl cyclase domain
Biosynthesis of cAMP from ATP
2nd c.458C>Tp.(Ile153Thr) 4/6 + 0/60,706
Interaction with ORAI1, STIM1,
PPP2CA and PPP2R1A
HSPG2 FAM23 NM_005529.7
1st c.3148G>Ap.(Gly1050Ser) 3/6 − 3/60,456 Laminin IV type A domain Component of vascular
extracellular matrix, regulation
of angiogenesis and cell growth2nd c.7406C>Tp.(Thr2469Met) 4/6 − 0/60,706
Immunoglobulin-like C2-type
domain
Abbreviations: DAMpred, disease-associated mutation prediction, affects protein structure (+), no effect on protein structure (−); ExAC, Exome Aggregation Consortium; Freq., frequency;
Path., pathogenicity, cAMP: cyclic AMP.
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Table 2. Candidate genes for germline colorectal cancer (CRC) predisposition selected after the two-hit prioritization strategy. In all cases, a first single nucleotide
variant (SNV)/indel hit was present in the germline and a second loss of heterozygosity (LOH) hit was identified in the matched-tumor sample.
Gene Family RefSeq Transcript Genetic Variant Path. Tools DAMpred ExAC Freq. Protein Domain Protein Function
BRCA2 FAM20 NM_000059.3 c.4963delTp.(Tyr1655fs*15) FS n.a. 0/60,706 -
Double-strand break repair via homologous
recombination, inherited predisposition to breast and
ovarian cancer
BLM FAMN4 NM_000057.4 c.2069C>Tp.(Pro690Leu) 6/6 + 1/60,570 Helicase ATP-binding domain
DNA helicase, double-strand break repair via
homologous recombination, regulation of cell cycle and
apoptosis, DNA replication, telomere maintenance
ERCC2 H458 NM_000400.3 c.688G>Ap.(Val230Ile) 4/6 − 0/60,706 Helicase ATP-binding domain
DNA helicase, transcription-coupled nucleotide excision
repair, regulation of cell cycle
FAT2 FAMN3 NM_001447.2 c.1643T>Cp.(Val548Ala) 5/6 − 0/60,706 Cadherin domain Regulation of cell proliferation, cell adhesion
IGF2R H466 NM_000876.3 c.232G>Ap.(Gly78Arg) 6/6 + 1/60,684 - Positive regulation of apoptosis
LATS2 H460 NM_014572.3 c.337G>Ap.(Asp113Asn) 5/6 − 1/56,138 Ubiquitin-associated domain Positive regulation of apoptosis, regulation of cell cycle
PARP2 FAM20 NM_005484.3 c.910G>Cp.(Glu304Gln) 3/6 − 3/60,208
Poly(ADP-ribose) polymerase
(PARP) alpha-helical domain
Base excision repair, extrinsic apoptotic signaling
pathway
PSMD9 H469 NM_002813.6 c.361A>Tp.(Ser121Cys) 3/6 − 30/60,148 PDZ domain
Subunit of 26S proteasome, regulation of apoptosis and
cell cycle, regulation of ubiquitin-protein ligase activity
RASSF6 H460 NM_201431.2 c.779C>Tp.(Pro260Leu) 6/6 − 53/60,475 Ras-associating domain Positive regulation of apoptosis
RECQL H466 NM_002907.4 c.221_225delinsAATGTp.(Pro74_Trp75delinsGlnCys) 6/6 + 0/60,706 -
DNA helicase, double-strand break repair via
homologous recombination, DNA replication
RERGL H466 NM_024730.3 c.362T>Cp.(Val121Ala) 6/6 + 54/60,446 -
Unknown (closely related to RERG, which functions as a
negative regulator of cell growth [14])
REV3L FAM3 NM_002912.4 c.559A>Tp.(Arg187Trp) 5/6 − 0/60,706
Exonuclease domain (family B
of DNA polymerases) DNA repair, translesion DNA synthesis
RIF1 H460 NM_018151.4 c.4262G>Ap.(Arg1421His) 4/6 + 5/59,938 -
Double-strand break repair via nonhomologous end
joining, telomere maintenance
SEC23B H470 NM_032985.5 c.531G>Cp.(Glu177Asp) 4/6 − 1/60,706 Sec23/Sec24 trunk domain
Intracellular protein transport, associated with inherited
cancer predisposition Cowden Syndrome
SMARCA4 FAM3 NM_003072.3 c.295C>Tp.(Arg99Trp) 5/6 − 1/60,196 -
Regulation of cell growth, regulation of cell cycle,
chromatin remodeling
STK11IP H470 NM_052902.4 c.1214C>Tp.(Pro405Leu) 5/6 − 51/59,930 -
Interaction with STK11 (serine/threonine kinase activity,
negative regulation of cell growth, Peutz-Jeghers CRC
predisposition syndrome)
Abbreviations: DAMpred: disease-associated mutation prediction, affects protein structure (+), no effect on protein structure (−); n.a., not available; ExAC, Exome Aggregation Consortium;
Freq., frequency; FS, frameshift; Path., pathogenicity.
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All variants located in the 12 final candidate genes were validated by the manual inspection
of WES data. In addition, a case-control enrichment analysis for the 12 final candidate genes was
performed using a publicly available independent cohort of 1006 patients of familial early-onset CRC
(CanVar) and the Exome Aggregation Consortium (ExAC) database. We checked if rare and potentially
pathogenic variants in the 12 final candidate genes were also present in this CRC cohort and tested if
they were more frequent than in the ExAC control dataset. Potentially pathogenic and rare variants
were found in CanVar for all 12 genes assessed. ADCY8, BLM, BRCA2, ERCC2, REV3L, RIF1, SEC23B,
SMARCA4 and STK11IP were highlighted for harboring a significant enrichment in CRC cases for
more than 50% of the potentially disrupting variants (Table S3).
2.2. Somatic Mutational Profiling Detected Hypermutated Tumors Compatible with A Germline Defect Etiology
Different somatic specific features were assessed in order to identify possible links with germline
CRC predisposition that could help in the selection of the most suitable candidate genes. Tumor
mutational burden analysis presented a large number of mutations per sample, with 5 out of 16 samples
showing a hypermutated profile with more than 90 mutations per megabase (Mb), and a median
of 58.8 mutations per Mb in the whole cohort (Figure 1). One of the hypermutated samples, H466
(96.9 mutations per Mb), was affected by the putative loss of function of a DNA repair-associated
gene according to the two-hit prioritization strategy, RECQL. A germline deficiency in the DNA repair
pathways affected by this gene could explain both the inherited predisposition to CRC and the elevated
tumor mutational prevalence shown by the patient. An ultrahypermutated sample with more than
500 mutations per Mb (sample H470) was also identified. Interestingly, no deleterious mutation in
POLE, POLD1 or the MMR genes was found in the germline or somatic profile of this patient.
Regarding mutational signatures, the typical profile of a microsatellite-stable and POLE-wild-type
CRC is shown by the mutational profile reconstruction using the 30 reference signatures of the
COSMIC database (Catalogue of Somatic Mutations in Cancer; https://cancer.sanger.ac.uk/cosmic/
signatures). This included a strong predominance of clock-like mutational signature 1, directly
associated with the age of onset, along with a low prevalence of signatures related with MMR deficiency
(signatures 6, 15, 20 and 26) and POLE mutations (signature 10). Specifically, signature 1 has been
linked with the spontaneous deamination of 5-methylcytosine at NpCpG trinucleotides leading to T/G
mismatches which are not repaired before DNA replication and, therefore, predominantly generate
C>T mutations. Interestingly, none of the other signatures currently associated with a particular
deficiency in a DNA repair pathway (signatures 2 and 13 with APOBEC activity, signature 3 with
double-strand break repair via homologous recombination and signatures 18 and 30 with base excision
repair) were detected as a relevant contributor in any of the analyzed tumor samples. Mutational
signatures 7 and 11 were the other two signatures with a greater prevalence in our cohort, although
they contributed just 6% to the profile reconstruction on average. A link between UV light exposure
and signature 7 has been consistently demonstrated, whereas signature 11 has been mostly associated
with alkylating chemotherapy treatments. Both etiologies were not apparently relevant for CRC
germline predisposition.
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Figure 1. Somatic mutational profile analysis performed with the Mutational Signatures in Cancer (MuSiCa) tool in 16 germline–tumor paired samples. (a) Mutational
prevalence (number of mutations per sequenced Mb). Hypermutated samples (≥90 mutations/Mb) are marked with an asterisk (*); (b) mutational signature refitting
analysis showing the contributions of the 30 Catalogue of Somatic Mutations in Cancer (COSMIC) reference mutational signatures in the mutational catalogues of the
samples of the study.
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3. Discussion
An integrated germline–tumor WES analysis was performed in 16 unrelated samples after
quality control filtering, resulting in the prioritization of 12 new candidate genes for CRC germline
predisposition. A germline SNV and a tumor SNV were identified in ADCY8 and HSPG2 genes,
whereas a germline SNV/indel and somatic LOH of the wild-type allele was predicted for BRCA2,
BLM, ERCC2, PARP2, RECQL, REV3L, RIF1, SEC23B, SMARCA4 and STK11IP.
ADCY8 is a membrane-bound enzyme that catalyzes the formation of cyclic AMP (cAMP) from
ATP. The cAMP pathway was already found to be associated with cancer, with the overexpression
of ADCY3 increasing oncogenic potential in gastric cancer cells [15] and ADCY8 acting itself as a
risk modifier in glioma [16]. HSPG2 encodes for the perlecan protein, an essential extracellular
matrix component. Its effect on CRC was described using cell lines and tumor xenografts and
allografts, where an oncogene role promoting tumor growth and angiogenesis was found [17]. Thus,
both genes were not in accordance with the TSG role expected for the genes prioritized by our
integrated germline–tumor analysis and were therefore discarded as the putative cause of the inherited
predisposition to CRC in the affected families.
A role in DNA repair, along with a previous association with hereditary cancer syndromes, drove
the prioritization of the germline SNV/indel and somatic LOH candidates. RECQL presented both
alterations in a patient with a hypermutated tumor, thus suggesting the hypothesis of a deregulation
of a DNA repair mechanism causing a rapid increase in the number of tumor mutations. In this
case, the RECQL variant (p.Pro74_Trp75delinsGlnCys) was not reported in ExAC and had a potential
disruptive effect in the protein structure (Table 2). This gene encodes for a DNA helicase belonging to
the RecQ family, responsible for the unwinding of double-stranded DNA and therefore implicated
in both DNA replication and repair [18]. Thus, the loss of function of RECQL would affect the
maintenance of chromosomal stability. In this regard, mutations in this gene have already been
linked to breast cancer predisposition [19]. Interestingly, other key members of the same protein
family have been associated with well-known recessive cancer predisposition syndromes (BLM, Bloom
syndrome; RECQL4, Rothmund–Thompson syndrome; WRN, Werner syndrome) [20]. BLM was
also found to be mutated in the germline DNA of one patient in our cohort and prioritized by our
two-hit integrated analysis. However, although the missense mutation found (p.Pro690Leu) was
predicted to be deleterious by different in silico tools and located at the helicase domain of the protein,
the tumor showed a low mutation burden. This could indicate either a non-significant effect of
the identified variant in BLM function, or an association with a distinct carcinogenic mechanism,
such us chromosomal instability (linked to a high number of CNVs and aneuploidy instead of SNVs).
Interestingly, our study highlights the link between CRC and breast cancer predisposition genes,
as well as the relevance of the Fanconi anemia pathway, as also underlined by previous studies [21–23].
BRCA2 and ERCC2 are also linked with classical cancer predisposition syndromes, hereditary
breast and ovarian cancer (HBOC) and xeroderma pigmentosum (XP), respectively [20]. In the case of
BRCA2, the germline frameshift variant found in family FAM20 (p.Tyr1655fsTer15) was classified as
pathogenic in ClinVar for HBOC. A role for this variant in the CRC predisposition was also suggested
in a previous study using the same cohort [21] and additionally supported by the presence of additional
breast cancer patients in the family (Figure S2). Accordingly, the strength of this association discarded
the other prioritized gene in the family, PARP2, which was also implicated in DNA repair. In addition,
BRCA2 mutations were found to be significantly enriched in the case-control analysis but not PARP2
mutations. On the other hand, ERCC2 encodes for a subunit of the DNA helicase in charge of the
nucleotide excision repair (NER) mechanism [24]. Homozygous or compound heterozygous mutations
in this gene are known to cause XP, a condition responsible for skin cancer predisposition [25]. In a
recent study, its association with breast and ovarian cancer susceptibility was also proposed [26].
Interestingly, a specific mutational signature characterized by a broad distribution of nucleotide
changes have recently been associated with somatic mutations in ERCC2 [27]. However, in the somatic
analysis performed for the patient harboring germline mutation in this gene (H458), this signature was
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not identified. In contrast, a strong predominance of age-related signature 1 was found (84% of somatic
mutations explained by this mutational source), along with a small contribution of signature 7 (9%)
(Figure 1). UV-derived mutations, commonly responsible for the latter signature, are repaired by NER,
potentially altered in this case by the ERCC2 inactivation and thus explain this specific contribution
to the somatic mutational profile observed. The germline mutation detected in our study (p.V230I)
is affecting the helicase ATP binding domain of the protein and has not been detected in the ExAC
database, thus suggesting its potential disruptive effect. In addition, disruptive variants in this gene
were found to be significantly enriched in the case-control analysis performed in familial early-onset
CRC patients.
REV3L and RIF1 were also prioritized by our integrated analysis and involved in translesion DNA
synthesis and nonhomologous end-joining DNA repair mechanisms, respectively [28–30]. Both carried
potentially pathogenic germline alterations according to the different evidence assessed (Table 2),
whereas the corresponding tumors showed a moderately mutated profile (61 and 30.8 mutations per
Mb, respectively). In addition, disruptive variants in both genes were found to be more significantly
enriched in cases than controls. REV3L was prioritized in family FAM3, where also a double
inactivation of SMARCA4 was predicted by our integrated analysis. The somatic LOH status of both
alterations were validated for this specific family using Sanger sequencing in previous studies [21,31].
The results did not confirm an LOH of the wild-type allele in the case of SMARCA4, whereas it was
detected for REV3L, thus supporting this gene as a better candidate.
An ultrahypermutated tumor was also found in one patient of our cohort (H470). The high
number of somatic mutations detected cannot be explained by classic somatic hypermutation drivers
(POLE, POLD1 and the MMR genes) [32], thus suggesting a specific alteration of another DNA repair
mechanism responsible for the phenotype. Interestingly, no gene implicated in this cellular mechanism
was identified by our integrated analysis. In contrast, SEC23B and STK11IP were the genes prioritized
through our approach for this patient. The specific functions of proteins encoded by these genes are not
directly related with CRC, although both are associated to cancer predisposition syndromes. SEC23B
is implicated in endoplasmic reticulum to Golgi apparatus transport [33], and has also been recently
associated with Cowden syndrome [34]. This inherited condition is linked to hamartomatous polyps
and elevated susceptibility to different epithelial cancers, being caused by germline mutations in PTEN
in most cases [34,35]. On the other hand, Peutz–Jeghers syndrome is an autosomal dominant CRC
predisposition syndrome also related to hamartomas and is mainly caused by germline mutations
in the TSG STK11 [5]. STK11IP, whose function is not currently broadly described, is known to be
interacting with STK11, and therefore potentially implicated in CRC predisposition [36].
Our development of a germline–tumor prioritization strategy was in accordance with recent
recommendations from the Germline/Somatic Variant Subcommittee (GSVS) of the Clinical Genome
Resource (ClinGen), on the use of tumor sequencing data for germline variant interpretation [37].
Even if the loss of heterozygosity and second mutation of the alternative allele assessment
were not directly recommended for clinical routine, both pieces of evidence supporting the
Knudson’s two-hit hypothesis could add a great value in the variant prioritization process in a
comprehensive germline–tumor WES study. In fact, the power of this approach have been proven
by previous studies using a similar methodology based in two-hit hypothesis assessment [13,38–41].
In addition, both tumor phenotypic features analyzed, tumor mutational burden and signatures,
were recommended to improve the support of the pathogenicity of germline variants by this and
additional studies [37,42]. However, no methylation data may impact the assessment of the two-hit
hypothesis, missing those genes affected by epigenetic silencing. In any case, further functional studies
and replication in additional cohorts will be needed in order to further confirm the identified potential
candidates for CRC germline predisposition.
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4. Materials and Methods
4.1. Patients
Eighteen unrelated Spanish patients (one per family) with unaffiliated strong CRC aggregation
compatible with an autosomal dominant pattern of inheritance and available germline and tumor
DNA samples were selected from a previously described cohort of 71 individuals from 38 families
(Figure S2). Families were selected based on the following criteria: three or more relatives with CRC,
two or more consecutive affected generations and at least one CRC diagnosed before the age of 60.
The entire cohort had germline WES data available from previous studies [12,21,31]. The presence of
germline alterations in well-known genes related with hereditary CRC syndromes (APC, MUTYH and
the DNA MMR genes) were previously discarded for all probands. The present study was approved by
the Institutional Ethics Committee (register number 2011/6440, date of approval 22/03/2011). Written
informed consent was obtained in all cases.
Matched tumor DNA samples were used to perform WES when available with an optimal
quantity and quality from our cohort of 38 CRC families. Tumor DNA was isolated from formalin-fixed
paraffin-embedded tissue using the QIAamp Tissue Kit (Qiagen, Redwood City, CA, USA) following
the manufacturer’s instructions and reaching a percentage of tumor cells of 70–80% among all
18 available samples. Germline DNA samples of other members of the family diagnosed with CRC,
advanced adenoma (i.e., lesion size ≥ 1 cm, villous architecture or high-grade dysplasia) or other
extracolonic cancers were also used in previous studies for germline segregation.
4.2. Whole Exome Sequencing
Germline WES data were available from previous studies [12,21,31]. WES was performed in
tumor samples of selected patients using the HiSeq2000 platform (Illumina, San Diego, CA, USA)
and SureSelectXT Human All Exon v5 kit (Agilent, Santa Clara, CA, USA) for exon enrichment.
Indexed libraries were pooled and massively parallel-sequenced using a paired-end 2 × 75 bp read
length protocol.
The quality control of sequencing data was made in all samples previous to their analysis using
the Real-Time Analysis software sequence pipeline (Illumina). Additionally, the proportion of all
shared exome regions sequenced with a coverage ≥ 10× was evaluated for tumor samples. A good
ratio of shared regions with high coverage (≥ 70%) was expected in good-quality samples, whereas
low-quality ones were characterized by a significant drop in this percentage.
WES data analysis was performed in accordance with the workflow displayed in Figure 2.
The Burrows–Wheeler Aligner (BWA-MEM algorithm) was used for read mapping to the human
reference genome (build hs37d5, based on NCBI GRCh37) [43]. PCR duplicates were discarded using
the MarkDuplicates tool from Picard, and then indel realignment and base quality score recalibration
were performed with the Genome Analysis Toolkit (GATK, Broad Institute, Cambridge, USA) [44].
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Figure 2. Methodology schematic for variant identification, showing the software used in each
analysis step for the different classes of genetic variation considered. WES, whole-exome sequencing;
BWA-MEM, Burrows-Wheeler Alignment Tool; GATK, Genome Analysis Toolkit; SNV, single
nucleotide variant; indels, insertion and deletion variants; CNV, copy number variant; LOH, loss
of heterozygosity; MuTect2, somatic SNV and indel variants caller.
4.3. Variant Calling and Filtering
4.3.1. SNVs and Indels
The GATK tools HaplotypeCaller and MuTect2 were used for SNV and short indels calling
for germline and tumor samples, respectively [44]. To improve germline variant filtering with
MuTect2, a panel of 71 available germline CRC samples from the whole cohort was used in the
case of five of the tumor samples, whereas an in-house pipeline from the CNAG-CRG (Centre Nacional
d’Anàlisi Genòmica-Centre de Regulació Genòmica, Barcelona, Spain) was implemented for the rest.
Regarding variant annotation, different databases were considered, including SnpEff, ANNOVAR
and dbNSFP for pathogenicity and variant position annotation. PhyloP (phyloP46way_placental
score ≥1.6), SIFT (prediction of damaging), PolyPhen2 (HumVar prediction of probably damaging or
possibly damaging), MutationTaster (prediction of disease-causing or disease-causing-automatic), LRT
(prediction of deleterious) and CADD (Phred score ≥15) were used for the pathogenicity prediction
of missense variants. Germline WES data was analyzed through an in-house R language pipeline
described in previous studies [12,21,31]. Functions related with CRC or cancer in general were
prioritized. DNA repair, apoptosis, autophagy, cell growth, cell proliferation, inflammatory response,
cell cycle, angiogenesis, cell differentiation, cell adhesion and chromatin modification, among others,
were included. Concerning tumor SNVs and indels, a similar filtering pipeline was used, restraining
selected variants to those having a coverage≥10× both in germline and somatic samples, an alternative
allelic frequency in the tumor ≥20%, and also selecting truncating or missense variants fulfilling at
least three of the missense pathogenicity tools criteria.
4.3.2. Copy Number Variants and Loss of Heterozygosity
The DNAcopy R package was used for the implementation of the circular binary segmentation
algorithm [45]. This was required for the fragmentation of the WES data in order to identify genomic
regions with an abnormal value of copy number. After segmentation, CoNIFER and Exome Depth
were used in germline data for CNV identification as previously described [12], whereas ALFRED was
used to predict the LOH of the wild-type allele in tumor samples [13].
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4.4. Variant Prioritization and Validation
After the automatic filtering process was performed for all variant types considered, a large
number of potentially pathogenic alterations were identified for every sample. Thus, an additional
prioritization process was required in order to select those actually relevant for the phenotype
under study. Taking advantage of the access to both germline and somatic WES data, an integrated
strategy based on Knudson’s two-hit hypothesis was developed in order to look for potential TSGs
associated with CRC germline predisposition. Genes with a deleterious germline variant (first hit,
SNV/indel or CNV) and a second mutational event in the tumor (second hit, SNV/indel or LOH)
were thus prioritized.
The prioritization process was completed with an additional stringent functional selection of
the candidate genes compatible with the TSG model expected. The most interesting final candidates
were manually curated according to functional evidence. In addition, the amino acidic position
of the variants within specific functional protein domains was checked using UniProtKB (http://
www.uniprot.org/) and InterPro (http://www.ebi.ac.uk/interpro/), as well as a possible 3D protein
structure destabilization effect by using the DAMpred tool (disease-associated mutation prediction;
https://zhanglab.ccmb.med.umich.edu/DAMpred/). Special attention was paid to genes previously
involved in predisposition to CRC and other neoplasms by reviewing the data present in OMIM
(Online Mendelian Inheritance in Man; http://www.omim.org/) and ClinVar (https://www.ncbi.nlm.
nih.gov/clinvar/).
The final prioritized variants were validated by manual inspection of the WES data with the
Integrative Genomics Viewer [46]. This high-performance data visualizer permits the exclusion of
any possible sequencing artifacts, especially those due to strand bias. This is the case when the
genotype information given by the data from the forward strand and the reverse strand is significantly
different [47]. The CanVar browser [48], a resource of variant level frequency data from cancer germline
sequencing studies containing 1006 familial early onset CRC patients, was also used to search for
additional variants in this independent familial CRC cohort. Only rare variants (ExAC allele frequency
< 0.1%) and potentially pathogenic (CADD Phred score > 15) were considered. Variant enrichment
was calculated by comparing the number of cases in the CanVar cohort with the number of controls in
the ExAC repository using a Fisher’s exact test.
4.5. Mutational Profiling and Mutational Signature Analysis
Somatic WES data was also specifically analyzed in order to look for particular tumor features
supporting a hypothesis for the inherited predisposition to familial CRC in the samples considered.
In this regard, both the tumor mutational burden and mutational signatures were taken into account.
The MuSiCa (Mutational Signatures in Cancer) web application was used to perform these analyses [49].
The prevalence of somatic mutations was described as the total number of SNVs per Mb accumulated
in a specific sample, assuming that an average WES sample accounts for 30 Mb with acceptable
sequencing quality values. With respect to mutational signatures, the original computational
framework described by Alexandrov and collaborators was considered [50,51]. Original mutational
profiles of the analyzed samples were reconstructed by the non-negative least squares algorithm using
the 30 reference signatures described in the COSMIC database [52].
5. Conclusions
Our integrated germline–tumor analysis based on Knudson’s hypothesis allowed the
identification of new potential genes implicated in the inherited predisposition to CRC. BRCA2,
BLM, ERCC2, RECQL, REV3L and RIF1 were among the most promising candidates, with some of
them previously associated with predisposition syndromes to other cancers. DNA repair was found to
be enriched among the genes prioritized by our approach, thus highlighting the importance of this
cellular mechanism in germline predisposition to colorectal carcinogenesis.
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